Physician profile
Ernest Tako
NPI 1689937518
$2,795.94
in general payments reported to CMS, 2019-2025
23 companies · $493 in 2025
The $493 reported for 2025 was more than what 80% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.35 · 2023: $281 · 2024: $1,923 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $1,599 · Food and Beverage: $1,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $1,599.00 |
| Food and Beverage | $1,098.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,588.23 | 2024 | |
| Astellas Pharma US INC | $182.64 | 2023-2025 | Veozah |
| Abbvie INC. | $146.81 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Biogen, INC. | $142.40 | 2025 | Zurzuvae |
| Myriad Women'S Health, INC. | $106.63 | 2023 | Myrisk |
| Shield Therapeutics INC | $93.24 | 2024 | |
| Organon LLC | $88.39 | 2023-2025 | Nexplanon, Jada System |
| Hologic Sales and Service, LLC | $61.67 | 2025 | Novasure, Myosure Tissue Removal Device, Acessa Provu System |
| Exeltis, USA INC. | $43.21 | 2024 | Slynd |
| Minerva Surgical, INC | $40.16 | 2023 | |
| Monaghan Medical Corporation | $36.42 | 2024 | Aeroeclipse, Aerobika |
| Pfizer INC. | $33.62 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $26.21 | 2024 | Gardasil, Gardasil 9 |
| Conmed Corporation | $25.00 | 2024 | Airseal |
| Exact Sciences Corporation | $23.38 | 2025 | Cologuard Collection Kit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $22.52 | 2025 | Dexcom G6 Transmitter |
| Millicent US INC | $22.50 | 2025 | Intrarosa, Femlyv |
| Pacira Pharmaceuticals Incorporated | $20.99 | 2023 | Exparel |
| Novo Nordisk INC | $20.67 | 2024 | |
| Mayne Pharma Commercial LLC | $20.64 | 2025 | |
| Northgate Technologies, INC. | $20.44 | 2024 | Stimsite |
| Sumitomo Pharma America, INC. | $15.19 | 2025 | Myfembree |
| Aspira Women'S Health INC | $14.98 | 2023 | Ova1 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ernest Tako listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.